SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-045606
Filing Date
2023-02-23
Accepted
2023-02-23 07:09:03
Documents
16
Period of Report
2023-02-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d438437d8k.htm   iXBRL 8-K 31691
2 EX-5.1 d438437dex51.htm EX-5.1 12102
3 EX-10.1 d438437dex101.htm EX-10.1 151178
7 GRAPHIC g438437g0220081125192.jpg GRAPHIC 1843
8 GRAPHIC g438437g76s01.jpg GRAPHIC 3699
  Complete submission text file 0001193125-23-045606.txt   375346

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA omga-20230222.xsd EX-101.SCH 2868
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE omga-20230222_lab.xml EX-101.LAB 17978
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE omga-20230222_pre.xml EX-101.PRE 11270
10 EXTRACTED XBRL INSTANCE DOCUMENT d438437d8k_htm.xml XML 3347
Mailing Address 20 ACORN PARK DRIVE CAMBRIDGE MA 02140
Business Address 20 ACORN PARK DRIVE CAMBRIDGE MA 02140 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 23655901
SIC: 2836 Biological Products, (No Diagnostic Substances)